FORM 4

Check this box if no longer subject

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT	<b>OF CHANGES II</b>	N BENEFICIAL	OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Harsanyi Zsolt				2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [ EBS ]									ck all app	tionship of Reportir all applicable) Director		rson(s) to Is			
(Last) 400 PRC	(Fir	st) (NAL DR, SUITE 4	Middle) 400			3. Date of Earliest Transaction (Month/Day/Year) 05/26/2022								Office below	er (give title w)		Other ( below)	specify	
(Street) GAITHE (City)	ERSBURG (Sta	ate) (Z	20879 Zip)	2 Doriva		4. If Amendment, Date of Original Filed (Month/Day/Year)  tive Securities Acquired, Disposed of, or Benef						Line)	Form Form Perso						
		Table	I - Nor	1-Deriva	tive	secu	rities	Acq	uirea,	DIS	posea of	, or E	3ene	ficial	iy Own	ea			
Dat			Date	onth/Day/Year)   if any		Execution Date,				es Acquired (A Of (D) (Instr. 3,			Benefic	ties cially Following	Forn (D) c	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	t (A) or (D)		Price	Transa	action(s) 3 and 4)			(1130.14)		
Common Stock <sup>(1)</sup> 05/2			05/26/	2022			A		8,446(2)	A \$0		\$0	38,052			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, ity or Exercise (Month/Day/Year) if any		Code ( 8)	ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)  Amount or Number of Title Shares		str.	. Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				

## **Explanation of Responses:**

- 1. Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated.
- 2. These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company.

## Remarks:

/s/ S. Scott Lieberman, 05/31/2022 Attorney-in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.